Citi is out with its report today on Gilead Sciences GILD, maintaining Hold.
In its report, Citi writes, "We rate the shares of Gilead Sciences Hold/High Risk (2H). According to our
estimates, Gilead is slated to post an 18% EPS CAGR from 2011-'14 due to its premier HIV franchise and driven by $6B in stock buybacks. However, Gilead's
main HIV products are expected to undergo patent expiration from 2017-'21, that will compound other patent expirations in 2014-'16, raising doubts about the
sustainability of profits in the out-years."
Citi maintains a $44 PT on GILD.
At the time of posting, shares of GILD were trading at $37.33, down 1.28% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in